MedTrace Logo

Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes

NCT01180530 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 358

Last updated 2017-02-08

No results posted yet for this study

Summary

This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Delivery Systems

Interventions

DEVICE

NovoPen Echo®

Prescribed insulin treatment delivered by NovoPen Echo®

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Canada
  • Finland
  • Israel
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180530 on ClinicalTrials.gov